Physician profile
Mark E Choquette
NPI 1366623886
$1,646.88
in general payments reported to CMS, 2019-2025
27 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $634 · 2022: $487 · 2023: $131 · 2024: $118 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $204.17 | 2021-2023 | |
| Lilly USA, LLC | $183.87 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $151.46 | 2021-2025 | Verquvo |
| Pfizer INC. | $142.17 | 2021 | |
| Paratek Pharmaceuticals, INC. | $108.99 | 2022-2025 | Nuzyra, Xhance |
| Medtronic, INC. | $103.42 | 2022 | |
| Vanda Pharmaceuticals INC. | $72.30 | 2024-2025 | Fanapt |
| Amgen INC. | $70.36 | 2021-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $68.10 | 2021-2024 | Airsupra |
| Eisai INC. | $61.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $59.20 | 2022 | |
| Novo Nordisk INC | $48.68 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $48.68 | 2022-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $47.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.89 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $29.26 | 2022-2023 | Quviviq |
| Lundbeck LLC | $29.16 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $28.16 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.95 | 2025 | Caplyta |
| Verona Pharma, INC. | $21.74 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $19.43 | 2023 | Tirosint, Licart |
| Otsuka America Pharmaceutical, INC. | $16.66 | 2023 | Rexulti |
| Adlon Therapeutics L.P. | $15.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.75 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.85 | 2025 | Trulance, Xifaxan |
| Athena Bioscience, LLC | $13.23 | 2023 | Qdolo |
| Genentech USA, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Choquette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.